GlassScriptPhysician profile
Joseph C White
NPI 1376516641
$1,663.58
in general payments reported to CMS, 2019-2025
23 companies · $549 in 2025
The $549 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $155 · 2022: $166 · 2023: $171 · 2024: $329 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,048.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $333.35 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Astrazeneca Pharmaceuticals LP | $222.21 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $167.83 | 2019-2025 | Wegovy |
| Recor Medical INC | $149.28 | 2025 | Paradise Ultrasound Renal Denervation System |
| Abbott Laboratories | $148.58 | 2023 | Freestyle Libre 3 |
| Pfizer INC. | $120.35 | 2019-2025 | |
| Lilly USA, LLC | $90.68 | 2022-2025 | Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $63.88 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $53.10 | 2024-2025 | Zoryve |
| Astellas Pharma US INC | $34.66 | 2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $28.74 | 2022 | |
| Dynavax Technologies Corporation | $27.11 | 2022 | |
| Amarin Pharma, INC. | $24.53 | 2019 | |
| Sanofi Pasteur INC. | $22.62 | 2019 | |
| Exact Sciences Corporation | $22.57 | 2025 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $22.38 | 2023 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $21.40 | 2024 | Strensiq |
| Avvisto Therapeutics, LLC | $21.10 | 2024 | Cycloset |
| Seqirus USA INC | $20.00 | 2019 | |
| Abbvie INC. | $18.96 | 2025 | |
| Phadia US INC. | $17.53 | 2025 | Immunocap |
| Janssen Pharmaceuticals, INC | $17.17 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.55 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.